Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker alleged that ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says.

Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster ...

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Weaver outlined her concerns with counterfeit weight-loss medication. “If there is, contaminants, allergens in it, that sort ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.